Global Teduglutide Drugs Market Size By Type (Gattex, Revestive), By Application (Hospital, Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Teduglutide Drugs Market was valued at USD 1.04 billion in 2023 and is projected to reach USD 2.27 billion by 2031, growing at a CAGR of 10.2% during the forecast period of 2023 to 2031. Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, has shown significant efficacy in treating Short Bowel Syndrome (SBS). The growing prevalence of SBS, increasing awareness among healthcare professionals, and advancements in biologics are driving the demand for teduglutide-based therapies. Market expansion is also being supported by rising clinical trials and regulatory approvals in emerging markets.

Drivers:

Rising Prevalence of Short Bowel Syndrome:

The increasing incidence of SBS, particularly among pediatric and adult patients who have undergone extensive bowel resection, is a key driver. Teduglutide offers long-term intestinal rehabilitation, reducing dependency on parenteral nutrition.

Advancements in Biologic Drug Development:

Innovations in peptide-based drug design, delivery mechanisms, and manufacturing technologies have led to improved therapeutic profiles and patient compliance, promoting wider acceptance of teduglutide.

Improved Diagnosis and Awareness:

Improved clinical guidelines and diagnostic accuracy have led to early detection of SBS. Enhanced physician awareness regarding teduglutide’s benefits is contributing to increased prescriptions.

Restraints:

High Cost of Therapy:

Teduglutide drugs come with a high price tag, limiting accessibility in low- and middle-income countries. Reimbursement challenges in certain healthcare systems further constrain market adoption.

Limited Patient Pool:

Despite being a serious condition, SBS remains a rare disease, resulting in a relatively small target population. This limits the scalability of teduglutide drug commercialization.

Opportunity:

Expansion in Emerging Markets:

Growing healthcare infrastructure in regions like Asia-Pacific and Latin America offers untapped opportunities for teduglutide drug manufacturers. Increasing awareness and regulatory support are facilitating new drug launches.

Pediatric Indication Expansion:

Ongoing clinical trials focusing on pediatric patients with SBS present an opportunity for label expansion. Approval in this segment could significantly enhance market growth.

Market by System Type Insights:

By formulation, injectable teduglutide holds the dominant market share in 2023. Due to its proven efficacy and bioavailability via subcutaneous administration, the injectable format continues to be the standard of care. However, the development of oral peptide delivery platforms is gaining attention and may disrupt the market in the coming years, pending regulatory success and patient acceptance.

Market by End-Use Insights:

Hospitals remained the leading end-user segment, accounting for over 60% of revenue in 2023. Teduglutide treatments are often administered under specialized supervision, making hospitals a preferred treatment setting. However, the homecare segment is projected to grow at the fastest pace, driven by innovations in self-administration devices and increasing patient preference for convenient care.

Market by Regional Insights:

North America dominated the global market in 2023, attributed to high awareness, robust healthcare infrastructure, and early adoption of advanced biologics. Meanwhile, Asia-Pacific is forecasted to witness the highest CAGR during the period due to expanding access to biologics, favorable government initiatives, and increasing prevalence of gastrointestinal disorders.

Competitive Scenario:

Key players in the Global Teduglutide Drugs Market include:

Takeda Pharmaceutical Company Limited (manufacturer of Gattex/Revestive)

Theravance Biopharma

Ferring Pharmaceuticals

Hanmi Pharmaceutical

Biocon Biologics Ltd.

These companies are actively engaged in R&D initiatives, expanding their clinical trial pipelines, and forming strategic partnerships. Notable developments include:

In 2024, Takeda launched a real-world evidence study evaluating long-term safety outcomes of teduglutide in diverse populations.

In 2023, Ferring Pharmaceuticals began a Phase II trial for an alternative teduglutide formulation targeting pediatric use.

Hanmi Pharmaceutical entered a licensing agreement to expand distribution in Southeast Asia.

Scope of Work – Global Teduglutide Drugs Market

Report Metric Details

Market Size (2023) USD 1.04 billion

Projected Market Size (2031) USD 2.27 billion

CAGR (2023–2031) 10.2%

Market Segments By Formulation (Injectable, Oral), By End-use (Hospitals, Homecare)

Growth Drivers Rising SBS prevalence, advancements in biologics, improved diagnosis

Opportunities Emerging market expansion, pediatric indication pipeline

Key Market Developments:

Takeda’s 2024 observational study on long-term real-world effectiveness of teduglutide boosted its credibility and prescriber confidence globally.

Ferring Pharmaceuticals’ pediatric trial in 2023 aimed at extending the indication of teduglutide to include children under 12 years.

Theravance Biopharma’s 2025 partnership with a biotech firm to explore new delivery systems for GLP-2 analogs.

FAQs:

1) What is the current market size of the Global Teduglutide Drugs Market?

The Global Teduglutide Drugs Market was valued at USD 1.04 billion in 2023.

2) What is the major growth driver of the Global Teduglutide Drugs Market?

The key growth driver is the rising prevalence of Short Bowel Syndrome (SBS) and advancements in GLP-2 biologic drug development.

3) Which is the largest region during the forecast period in the Global Teduglutide Drugs Market?

North America is the largest region due to strong healthcare infrastructure and high awareness levels.

4) Which segment accounted for the largest market share in the Global Teduglutide Drugs Market?

The Injectable Teduglutide segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Teduglutide Drugs Market?

Key players include Takeda Pharmaceutical Company, Ferring Pharmaceuticals, Theravance Biopharma, and Biocon Biologics Ltd..